The global benign prostatic hyperplasia treatment devices market size was estimated at USD 1.42 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 8.90% from 2023 to 2030. The growth of the market for benign prostatic hyperplasia (BPH) treatment devices has been spurred by aspects such as rising patient awareness of available treatment options, increasing prevalence of urological disorders, and technological advancements. Furthermore, growing demand for novel minimally and non-invasive technologies such as laser (HoLEP and ThuLEP) and Aquablation treatments provide fewer adverse effects, as well as faster recovery periods than open surgical techniques, which is anticipated to increase the demand for BPH treatment device in near future.
The prostate grows larger as a result of BPH. Due to aging the majority of the male population experience prostate-related issues such as BPH. A sudden urge to urinate and difficulties urinating are symptoms associated with benign prostatic hyperplasia. The treatment options include medication, surgery, and minimally invasive procedures. The market for devices used to treat BPH is expanding further at an accelerated rate due to the rising elderly population.
For instance, as per the reports of the World Health Organization (WHO), around 80% of elderly people by 2050 will reside in nations with low or middle income. It is anticipated that the number of persons 80 years of age or older will triple between 2020 and 2050, reaching around 426 million. The probability of being diagnosed with benign prostatic hyperplasia (BPH) rises with age, which is the primary risk factor. Thus, the market, according to the study is expected to have explosive growth in the coming years as the geriatric population increases.
The market is also expected to grow because of the rise in demand for minimally invasive procedures and innovations related to novel and enhanced BPH treatment devices. Minimal invasive surgeries mostly involve outpatient surgeries which are performed under minimal anesthesia. The recovery rate for these surgeries is fast compared to the traditional open surgeries. Moreover, the increasing adoption of robot-assisted surgical methods and the availability of favorable reimbursement options drive the market growth.
For instance, in May 2023, the company Teleflex Incorporated announced the novel findings from the data obtained from the research findings stating the long-term efficacy of the prostatic urethral lift procedure using the UroLift System which showed fewer complications when compared to the other traditional minimal invasive BPH procedures. The UroLift system is considered the most widely used minimal invasive benign prostatic hyperplasia treatment procedure adopted by the doctors in U.S. to treat patients. Thus, due to such factors, the demand for the market will increase in the near future.
The industry is growing due to ongoing studies and research projects focused on enhancing existing devices and creating new treatment choices. For instance, in June 2023, Olympus Corporation launched a novel electrosurgical generator. The electrosurgical generator was made available on the market for use in the treatment of enlarged prostate and bladder cancer. By offering a variety of vaporization buttons, band electrodes, resection loops, and needles, the electrosurgical generator (ESG-410) provides alternatives and efficiency in the treatment of benign prostatic hyperplasia or an enlarged prostate.
The demand for benign prostatic hyperplasia devices could experience additional growth due to the expanding healthcare sector in emerging nations and technological advancements in the devices are expected to increase market growth. The market for devices to treat benign prostatic hyperplasia mayface challenges due to product recalls and lack of knowledge about treatment, cure, and overall prostate health among people.
Minimal invasive surgery held the largest market share of around 72.16% in 2022. Compared to open surgery, minimally invasive procedures provide effective treatment with fewer risks and quicker recovery times. Significant improvements and advances have been made in the minimally invasive surgery field recently, with an emphasis on increasing patient outcomes and reducing intrusion. The accuracy rate of minimal invasive surgery is high as it involves the use of robot-assisted devices and instruments for better visualization and diagnosis of the internal organs.
The novel product and devices launch for minimal invasive procedures boosts the market. For instance, a study published in 2023 by Olympus Corporation stated the results showing that the minimally invasive iTind treatment offered BPH patients long-lasting relief of more than four years. Lower urinary tract symptoms caused by BPH were significantly reduced because of the procedure, and the International Prostate Symptom Score and Quality of Life were both improved for up to 50 months and over 79 months after the surgery. Thus, due to such advancements, the demand for benign prostatic hyperplasia (BPH) treatment devices will increase in the near future.
The segment is also anticipated to grow at the highest CAGR during the forecast period. This is a result of benign prostatic hyperplasia's increased incidence. The risk of dilutional hyponatremia can be avoided by using the holmium laser combination with a standard saline irrigant. In addition, the holmium laser's hemostatic characteristics produce greater hemostasis, reducing the possibility of bleeding. These characteristics of holmium laser prostate ablation are anticipated to accelerate the segment's expansion.
The transurethral resection of the prostate (TURP) segment held the largest market share of around 25.32 % in 2022. The surgical treatment known as TURP is used to treat moderate to severe BPH. For many years, TURP has been a common surgical procedure used to treat BPH, and it has a demonstrated track record of successfully reducing urinary symptoms. Although it is an invasive procedure that can involve a hospital stay, there are risks and adverse effects that could occur, including retrograde ejaculation, bleeding, and infection.
For instance, as per the reports published by Mayo Clinic in 2022, men with moderate to severe urinary issues who do not receive a cure from medicines are typically thought to be candidates for TURP. TURP often produces rapid symptom relief. Within a few days, most men have a much greater urine flow. Sometimes maximum medical care is required to relieve symptoms, especially years later.
The robot-assisted laparoscopic prostatectomy (RASP) segment is expected to grow at the highest CAGR during the forecast period. The robotic system improves a surgeon's flexibility and accuracy, enabling delicate movements and fine dissection. Smaller incisions are used during robot-assisted laparoscopic prostatectomy than during open surgery, which results in less pain, scarring, and blood loss. Compared to open surgery, patients often stay in the hospital for fewer days and recover more quickly. Lower risk of infection and consequences may also result from minimally invasive procedures.
According to the article published in the Journal of Prostate Cancer in November 2022, for the management of BPH brought on by a big prostate gland, RASP has evolved into a size-independent therapy. Robot-assisted laparoscopic prostatectomy offers a quicker and better treatment when compared to prostate laser endoscopic enucleation. Also, the reports published by The Havard Gazette, in March 2022, stated that robot-associated prostate surgery requires shorter hospital stays and has fewer complications such as blood clots, and UTI infections compared to traditional open surgery procedures.
The resectoscopes segment held the largest market share of around 21.70% in 2022. Resectoscopes are specific types of endoscopes that are used for procedures on the bladder, uterus, prostate, or urethra. TURP surgery uses a resectoscope, an advanced surgical device used for the treatment of medium to severe BPH. Although TURP with a resectoscope continues to be the gold standard for treating BPH, there are several minimally invasive options available. These include water vapor therapy, microwave therapy, and laser therapy. These alternatives aim to lower the procedure's invasiveness and could shorten recovery periods. Resectoscopes have transformed the field of urology by allowing surgeons to carry out complicated surgeries with less trauma to patients and shorter recovery times than with open surgery.
The urology laser segment is expected to grow at the highest CAGR during the forecast period. The increasing research and manufacturing facilities for developing the laser system for BPH treatments drive the segment growth. Due to their accuracy and lower risk of complications compared to other BPH open surgeries, urology lasers have become favorable among patients and medical professionals. The article published in Urology Times in July 2023, demonstrated the HoLEP developments in the treatment of benign prostatic hyperplasia. The pulse-modulated holmium lasers enabled the surgeons to carry out outpatient surgery for BPH.
The American Urological Association recommends HoLEP lasers for prostates of any size. It is customizable and can be used for prostates of any size, as well as for individuals who might require a second operation, have bleeding problems, or have poor bladders. After undergoing a HoLEP operation, very few people need additional surgeries over the course of their lifespans. The increasing demand for urology lasers for surgical treatments drives the segment growth.
The hospitals segment held the largest market share of around 64.77% in 2022. The rise in urology-related disorders and the increasing prevalence of BPH treatments drive the segment growth. For the diagnosis and care of BPH, hospitals are important. They serve as the primary site for handling BPH patients since they frequently have access to cutting-edge medical technology and a staff of trained healthcare specialists. Hospitals can undertake surgical procedures like TURP or HoLEP when BPH symptoms are severe or other therapies have been unsuccessful.
Moreover, hospitals provide better healthcare facilities and provisions to treat complex surgeries. For instance, as per the reports of NHS Fife, in May 2023, Queen Margaret Hospital of Scotland was the first to offer cutting-edge surgical treatment of an enlarged prostate using the iTind device. The new procedure involved inserting a tiny device temporarily into the prostate for 5-7 days before totally removing it. After being implanted, the iTind swells and exerts mild pressure, remodeling the tissue at the bladder's opening and forming a wider route where urine can flow. Patients can be treated as day cases and go home the same day because the procedure is minimal invasive than conventional surgical techniques.
The hospitals segment is also expected to grow at the highest CAGR during the forecast period. An increasing number of patients being admitted to hospitals due to surgeries, therapies, and treatments is projected to favor the BPH treatment device market’s growth. Thus, subsequent increase in the number of patients across the globe, the launch of technologically advanced products, and favorable reimbursement policies are leading to a growing demand for hospital treatments. The rising awareness about the availability & advantages of advanced medical facilities available at hospitals is expected to help this segment grow over the forecast period.
North America dominated the BPH treatment device market with a share of 34.59% in 2022, owing to the presence of key manufacturers such as Urologix, LLC, Boston Scientific Corporation, Dornier MedTech, and Olympus America in the region. Furthermore, the rising prevalence of urology disorders, and increasing demand for minimally invasive surgical procedures are driving the market growth. Also, increasing incidences of diabetes and obesity lead to the risk of BPH disorders in men which boosts the BPH devices industry growth. For instance, the 2022 National Diabetes Statistics Report was recently made available by the Centers for Disease Control and Prevention. According to this study, there are more than 130 million persons in the US who have diabetes or prediabetes.
Asia Pacific is expected to grow at the highest CAGR during the forecast period due to factors such as technological advancements, and increasing acquisitions among the key players to product portfolio expansion. For instance, in May 2021, the acquisition of Medi-Tate, a manufacturer of medical equipment, was announced by Olympus Corporation. Olympus strengthened its position as an in urological devices and developed its business line by providing treatment for benign prostatic hyperplasia. Furthermore, increased R&D expenditure by manufacturers and increased government efforts are significantly contributing to regional market growth.
Key players are focusing on the launch of innovative treatments of medical devices, growth strategies, technological advancements, and product approvals. For instance, in May 2022, The Hybrid Thulium laser treatment device, RevoLix HTL from OmniGuide Holdings was approved by the FDA of the U.S. For urology patients having stone management procedures and BPH, RevoLix therapy is based on a variety of pulsed and continuous wave Thulium YAG lasers. The enucleation (ThuLEP), vaporesection (ThuVARP), tissue vaporization (ThuVAP), and vapoenucleation (ThuVEP) technologies used by RevoLix Thulium Lasers have been tailored to cure BPH efficiently. These advancements in the BPH treatment device market are anticipated to boost the market growth over the forecast period. Some prominent players in the global benign prostatic hyperplasia treatment devices market include:
Boston Scientific Corporation
Endo Pharmaceuticals Inc.
Richard Wolf GmbH
PROCEPT BioRobotics Corporation
Market size value in 2023
USD 1.53 billion
Revenue forecast in 2030
USD 2.79 billion
CAGR of 8.90% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million/billion and CAGR from 2023 to 2030
Treatment, procedure, product, end-use, region
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Denmark; Sweden; Norway, Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Revenue, competitive landscape, growth factors, and trends
Key companies profiled
Karl Storz, Boston Scientific Corporation; Olympus America, Endo Pharmaceuticals Inc.; biolitec AG, Medifocus; Cook Medical; Teleflex Incorporated; Urotronic; Coloplast Corp; Richard Wolf GmbH; PROCEPT BioRobotics Corporation
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global benign prostatic hyperplasia treatment devices market report based on treatment, procedure, product, end-use, and region:
Treatment Outlook (Revenue, USD Million, 2018 - 2030)
Minimal Invasive Surgery
Procedure Outlook (Revenue, USD Million, 2018 - 2030)
Transurethral Resection Of The Prostate
Prostate Laser Surgery
Transurethral Microwave Thermotherapy
Transurethral Needle Ablation Of The Prostate
Prostatic Urethral Lift
Water Vapor Therapy
Robot-assisted Laparoscopic Prostatectomy
Prostatic Artery Embolization
Bipolar Enucleation Of Prostate
Transurethral Incision Of The Prostate
High-Intensity Focused Ultrasound
Product Outlook (Revenue, USD Million, 2018 - 2030)
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Research & Manufacturing
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East and Africa (MEA)
b. The global benign prostatic hyperplasia treatment devices market is expected to grow at a compound annual growth rate of 8.9% from 2023 to 2030 to reach USD 2.79 billion by 2030.
b. The global benign prostatic hyperplasia (BPH) treatment device market size was estimated at USD 1.42 billion in 2022 and is expected to reach USD 1.53 billion in 2023
b. North America dominated the BPH treatment device market with the share of 34.59% in 2022 owing to the presence of key manufacturers such as Urologix, LLC, Boston Scientific Corporation, Dornier MedTech, and Olympus America in the region. Furthermore, rising prevalence of urology disorders, and increasing demand for minimally invasive surgical procedures are driving the benign prostatic hyperplasia (BPH) treatment device market growth in this region. Also, increasing incidences of diabetes and obesity leads to the risk of BPH disorders in men which boosts the BPH devices industry growth.
b. Some key players operating in the benign prostatic hyperplasia treatment devices market include Karl Storz, Boston Scientific Corporation, Olympus America, Endo Pharmaceuticals Inc., biolitec AG, Medifocus, Cook Medical, Teleflex Incorporated, Urotronic, Coloplast Corp, Richard Wolf GmbH, PROCEPT BioRobotics Corporation.
b. The market for BPH treatment devices has been spurred by aspects such as rising patient awareness of available treatment options, increasing prevalence of urological disorders, and technological advancements. Novel, minimally and non-invasive technologies such as laser (HoLEP and ThuLEP), and Aquablation treatments provide fewer adverse effects, as well as faster recovery periods than open surgical techniques, which in turn, is anticipated to increase the demand for benign prostatic hyperplasia (BPH) treatment device in near future.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
"The quality of research they have done for us has been excellent."